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Abstract 
A library of novel dispiro compounds containing oxindole-pyrrolo-carbazole hybrid frame works 
has been synthesized in a fully regio- and stereoselective fashion by the three-component 1,3-
dipolar cycloaddition of azomethineylides generated in situ from the condensation of isatins and 
benzylamine with 2-arylidene/heteroarylidene-2,3,4,9-tetrahydro-1H-carbazole-1-one. The 
structures of the compounds were established by FT-IR, 1H NMR, 13C NMR, X-ray diffraction 
and elemental analysis. The synthesized dispiro heterocycles have been screened for in vitro 
cytotoxic activity by MTT assay and displayed enviable growth inhibition on both the cancer cell 
lines i.e. breast cancer cell line MCF-7 and lung cancer cell line A-549. Morphological changes 
and apoptosis induction have been studied by inverted light microscopic, fluorescent microscopic 
techniques and by flow cytometry analyses. The preliminary structure activity relationships were 
also carried out. Data indicated that among dispiro-carbazole compounds,6-chloro-4'-(thiophen-
2-yl)-5'-phenyl-3,4-dihydrodispiro[carbazole-2,3'-pyrrolo-2',3''-indole]-9(H)-1,2''-dione 7e could 
be exploited as a significant therapeutic drug against breast cancer as well as lung cancer cell 
proliferation. 
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1. Introduction 
Breast cancer and lung cancer are the two most recurrently diagnosed malignant tumors 
worldwide. Variety of breast cancer drugs such as Tamoxife, Letrozole, Docetaxyl etc. are being 
prescribed to the patients as preventive and curative treatments [1,2]. However undue toxicity 
and side effects in these medicines spoil their efficacy [3-5]. Despite recent advances made in 
anti lung cancer drug development, the presence of resistance to chemotherapeutic agents is a 
major obstacle to the effective treatment of lung cancer [6]. Consequently, discovering novel, 
puissant molecular entities as potential anti cancer drugs with improved efficacy and resistance 
to complement the present chemotherapeutic strategies is highly desired. Interestingly natural 
products provide a healthy source for such compounds. The spirooxindole-pyrrolidine nucleus is 
often found in the molecular framework of many natural products, vizhorsfiline [7], coerulescine 
[8], elacomine [9], isopteropodine [10], formosanine [11], rychnophyilline [12] and 
spirotryprostatins A and B [13] etc. It possess a myriad of biological activities such as inhibition 
of the mammalian cell cycle at G2/Mphase [14], inhibition of microtubule assembly [15], 
modulation of the function of muscarinic serotonin receptors [16] and malignant glioma GAMG 
[17], and anticancer [18], antimicrobial [19] and local anesthetic [20] activities. 
Carbazole and its derivatives represent an important class of bio-active heterocycles. 
Many natural products and drug molecules with the carbazole framework exhibit a broad range 
of biological and pharmacological activities [21-28]. In particular, carbazole derivatives show 
significant antitumor activity [29-31]. For example, glybomine B and C showed significant 
antitumor-promoting activity, which was confirmed by the inhibiting effect of these alkaloids in 
conjunction with the tumor promoter 12-o-tetradecanoylphorbol-13-acetate (TPA) [32], while 
heptaphylline and 7-methoxyheptaphylline displayed strong cytotoxicity against NCI-H187 and 
KB cell lines [33]. In addition carbazole arrests the tumor cell cycle at the M phase and induces 
apoptotic cell death by increasing expression of p-53 and promoting bcl-2 phosphorylation 
[34,35] (Figure 1). 
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The dominance by these two pharmacophores (carbazole and spiro-pyrrolooxindole) in 
nature and their impact in medicinal chemistry inspired us to develop new molecular hybrids by 
incorporating both the frameworks for our anticancer studies. Mostly, design of the hybrid drugs 
aims to circumvent the drug resistance, minimize the risk of drug-drug interactions, 
counterbalance the known side effects associated with the other hybrid part and amplify the 
activity through the interaction with multiple targets as one single molecule [36,37]. Now, hybrid 
drug design has emerged as a premier tool for the discovery of innovative anticancer therapies 
that can potentially overcome most of the pharmacokinetic drawbacks encountered when using 
conventional anticancer drugs.  
The 1,3-dipolar azomethineylide cycloaddition is a powerful tool for the construction of 
five-membered heterocycles and spiro-compounds [38] in a highly regio- and stereoselective 
manner [39]. Azomethineylides are reactive and versatile 1,3-dipoles, which readily react with 
diverse dipolarophiles with exocyclic double bonds to afford spiro-heterocycles [40]. 
Herein, we report a regio- and stereoselective one-pot method for the synthesis of a novel 
class of polynuclear dispiroheterocyclic structures comprising spiro-pyrrolooxindole and 
carbazole moieties. The synthesis was accomplished by 1,3-dipolar cycloaddition of azomethine 
ylides generated in situ from isatins and benzylamine to 2-arylidene/heteroarylidene-2,3,4,9-
tetrahydro-11H-carbazole-1-one. All the newly synthesized compounds were subjected to 
cytotoxic screening against breast cancer cell line MCF-7 and lung cancer cell line A-549. 
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Although there are reports available for the synthesis of substituted spiro-pyrrolooxindole, there 
seems to be no reports to the best of our knowledge for the synthesis of a rare class of 
dispiropyrrolooxindole having keto carbazole skeleton. 
 
2. Results and discussion 
2.1. Chemistry 
The dipolarophiles 3 employed in the present work were synthesized by the reaction of 
2,3,4,9-tetrahydro-1H-carbazole-1-one 1 with aryl/hetroaryl aldehydes 2 in the presence of 
alcoholic KOH in good yields at room temperature (Scheme 1). 
 
 
The structural elucidation of all the dipolarophiles 3 (a-i) was done with the help of 
spectroscopic (FT-IR, 1H-NMR & 13C-NMR) and elemental analysis data. The FT-IR spectrum 
of 3a showed the characteristic absorptions of an indole NH at 3290 cm-1 and a carbonyl group at 
1644 cm-1. The 1H NMR spectrum of 3a showed a broad singlet at δ 11.64 ppm attributed to the 
indole NH proton and a singlet at δ 8.27 ppm due to the presence of C5-H. Multiplet signals in 
the region of δ 7.68-7.34 ppm arise from the six aromatic protons, while a multiplet at δ 7.12-
6.98 ppm was assigned to the C7 and C2 aromatic and olefinic protons. The methylene protons of 
C3 and C4 appeared as two multiplets centered at δ 3.04 and 3.01 ppm respectively. A singlet at δ 
2.50 ppm accounts for three methyl protons at C6 position. The 
13C NMR spectrum revealed the 
presence of 20 carbons. A signal resonating at δ 179.5 was attributable to the carbonyl carbon. 
The universal validity of the reaction was tested with other substituted derivatives 3 (b-i). 
The choice of an appropriate reaction medium is of crucial importance for successful 
synthesis. Initially, the three component reaction of 2-arylidene/heteroarylidene-2,3,4,9-
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tetrahydro-1H-carbazole-1-one 3a, isatin 4 and benzylamine 5, as a simple model substrate, was 
investigated to establish the feasibility of the strategy and optimize the reaction conditions. 
Various solvents such as EtOH, MeOH, 1,4-dioxane, acetonitrile, toluene, EtOH/dioxane and 
MeOH/dioxane were screened. MeOH/dioxane (Table 1, entry 7) emerged as the solvent of 
choice, producing the highest yield (87 %) of the target compound. 
 
Table 1.Solvent screening for the Synthesis of dispiro compound 7a 
Entry Solvent Reaction time Yield (%) 
1. EtOH 7 56 
2. MeOH 7 64 
3. 1,4-Dioxane 8 70 
4. CH3CN 10 52 
5. Toluene 10 38 
6. EtOH/1,4-Dioxane 7 73 
7. MeOH/1,4-Dioxane 5 87 
 
The one pot regioselective synthesis of compounds 7 (a–i) has been performed by taking 
2-arylidene/heteroarylidene-2,3,4,9-tetrahydro-1H-carbazole-1-one 3 (a–i) (0.001 mol), isatin 4 
(0.001 mol) and benzylamine 5 (0.001 mol) in dioxane and methanol under reflux conditions. 
After completion of the reaction as evident from TLC, the solvent was removed and the crude 
product was purified by column chromatography to obtain pure 4′-arylidene/heteroarylidene-5'-
phenyl-3,4-dihydrodispiro[carbazole-2,3'-pyrrolo-2',3''-indole]-9(H)-1,2''-dione 7. The reaction 
proceeds through decarboxylative condensation of isatin 4 with benzyl amine 5 to generate 
unstabilize azomethineylide, which subsequently undergoes 1,3-dipolar cycloaddition with the 
dipolarophile 3 to afford novel cycloadduct 7 as a single regioisomer (Scheme 2). 
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We next explored the scope and generality of this three component cycloaddition reaction 
with substrates having (i) aryl rings bearing electron-withdrawing and electron releasing 
substituents and (ii) heteroaryl rings at the arylidene side chain. Moreover, the carbazole core 
was either unsubstituted or substituted with electron-releasing (methyl) or electron-withdrawing 
(Cl) groups. These structurally and electronically varied starting materials reacted efficiently 
with isatin and benzylamine, affording the corresponding cycloadducts 7 in good yields under 
the same set of reaction conditions in all cases (Table 2). 
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Table2. Synthesis of a library of spiropyrrolidinyloxindole-carbazole hybrids via 1,3-dipolar 
cycloaddition reaction with variety of aromatic aldehydes were executed. 
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The products 7(a-i) were characterized unambiguously by spectroscopic, crystallographic 
and analytical studies. The FT-IR spectrum of 7a revealed prominent absorptions at 3419, 3322 
and 3222 cm-1due to indole NH, carbazole NH and pyrrolo NH stretchings respectively. The 
peak at 1696 cm-1 is due to the carbonyl of indole ring whilst a peak at 1617 cm-1 is assignable to 
the carbazole carbonyl group. In the 1H NMR spectrum of 7a a doublet appeared at δ 4.69 ppm 
(Jcis = 10.0 Hz) due to C4' proton, which confirms the formation of cycloadduct. If the other 
possible regioisomer 8 had been formed then the 1H NMR spectrum would have shown a singlet 
for C4' proton instead. A pair of broad singlets appeared at δ 11.18 and δ 10.18 ppm 
corresponding to carbazole NH and oxindole NH respectively. A doublet at δ 7.50 ppm (Jo = 7.4 
Hz) accounted for C8 and C7'' aromatic protons and the aromatic protons on C5'''' and C3'''' 
resonated as a multiplet at δ 7.38 ppm. A multiplet in the region of δ 7.26-7.22 ppm accounted 
for the four aromatic protons on the substituted phenyl ring. The three aromatic protons in the 
C6'', C6'''' and C2'''' positions showed a multiplet in the region between δ 7.18-7.13 ppm. The C5 
proton appeared as a singlet at δ 7.09 ppm. Two doublets at δ 7.05 and δ 6.97 (Jo=7.4 Hz) ppm 
corresponding to C4'' and C7 protons. Three triplets appeared at δ 6.84, 6.56 and 6.54 ppm (J = 
7.4, 7.2 and 7.2 Hz) due to C5'', C4''' and C4'''' protons respectively. The C5' proton occurred as 
doublet of doublet at δ 5.45 ppm (J1,2-cis = 5.6 Hz & J1,2-cis = 10.0 Hz). The –NH proton of pyrrolo 
moiety resonated as a doublet at δ 3.61(J1,2-cis = 5.6 Hz) ppm. Methylene protons of C4 and C3 
appeared as multiplets centered at δ 2.57 and 2.47 ppm respectively. A singlet at δ 2.22 ppm 
assigned to the C6-CH3 protons. In 
13CNMR spectrum of 7a, the peaks at δ 72.3 and δ 61.5 ppm 
corresponded to the two spiro carbons. The oxindole ring carbonyl resonated at δ 180.5 ppm, and 
benzoylcarbonyl resonated at δ 191.5 ppm. Scrutiny of all spectral data confirmed the formation 
of the dispiropyrrolo derivatives, 4′-arylidene/heteroarylidene-5'-phenyl-3,4-
dihydrodispiro[carbazole-2,3'-pyrrolo-2',3''-indole]-9(H)-1,2''-dione 7. 
In order to verify the structure of 7a, a single crystal was obtained and analyzed by X-ray 
crystallography (Figure 2), which clearly indicated the formation of dispiro scaffold. Similarly, 
by straightforward considerations, the 1H and 13C chemical shifts of other derivatives 7(b-i) were 
also assigned. 
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Figure 2. Structure of 7a with the atomic numbering scheme shown. Hydrogen atoms omitted 
and only one position of disorder phenyl ring (C29-C34) shown for clarity.  Thermal ellipsoids 
depicted at the 50% probability level. 
 
A proposed mechanism for the regio- and stereoselective formation of the hybrid 
heterocycles 7(a-i) is presented in Scheme 3. The azomethine ylide 6a generated in situ from the 
reaction of isatin 4 with benzylamine 5, has one potential nucleophilic carbon, which 
subsequently undergoes 1,3-dipolar cycloaddition with the electron deficient β-carbon of the 
dipolarophile 3 to afford novel cycloadduct 7 as a single regioisomer. Control of the relative 
stereochemistry at the spiro centre was observed. Accordingly the observed regioisomer 7 via 
path A is more favorable because of the secondary orbital interaction [41] which is not possible 
in path B for getting other isomer 8. 
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2.2. Biological evaluation  
2.2.1. In vitro cytotoxic activity 
Anti-proliferative activity of the newly synthesized dispiro compounds 7(a-i) was 
examined in two human cancer cell lines, MCF-7 breast cancer and A-549 lung cancer using 
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MTT assay. Cisplatin is one of the most effective broad-spectrum anticancer drugs. Cisplatin 
enters cells via multiple pathways and forms different DNA–platinum adducts while initiating a 
cellular self-defense system by activating or silencing a variety of different genes [42]. Hence, 
we chose cisplatin as reference drug. Three independent experiments in triplicate were 
performed for the determination of sensitivity to each compound. The percentage cell viability 
was determined using the following formula, and the relationship between percentage cell 
viability and drug concentration was plotted to obtain the survival curve of the tested cancer cell 
lines. The response parameter calculated was the IC50 value, which corresponds to the 
concentration required for 50% inhibition of cell viability. The results are summarized in Table 
3. The in vitro cytotoxic activity of the synthesized compounds (7e and 7d) (10-100 µM 
concentrations) against both cancer cells has been presented in Figure 3. The experimental 
results demonstrate that all the compounds have the ability to inhibit cell proliferation in a dose 
dependent manner. 
 
 
Table 3. In vitro cytotoxicity and IC50 (µM) 
Compounds MCF-7a A-549b 
7a 19±1.4 18±1.5 
7b 18±0.8 15±1.4 
7c 15±1.5 17±0.5 
7d 14±0.8 15±1.4 
7e 13±1.6 14±1.2 
7f 15±0.8 16±1.5 
7g 18±1.7 20±1.4 
7h 19±0.8 18±1.4 
7i 17±0.8 21±1.4 
Cisplatin 9±1.0 10±1.5 
Bold indicates more active compounds. 
a breast cancer. b lung cancer.  
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As shown in Table 3, it was obvious that the synthesized dispiro-carbazole compounds 
displayed significant to modest growth inhibitory activity against the tested cancer cell lines. 
Investigations of the cytotoxic activity revealed that majority of the synthesized compounds 
exhibited potent anticancer activity against both the cancer cell lines, MCF-7 and A-549. Among 
the newly synthesized spiro compounds, compound 7e was found to be the most promising 
derivative against MCF-7 with IC50 values 13±1.6 μΜ compared to the IC50 value of cisplatin 
(9±1.0 μΜ). The next most outstanding compounds are 7d and 7f which displayed stronger 
cytotoxicity against MCF-7 cell line with IC50 values 14±0.8 and 15±0.8 μΜ respectively. 
Furthermore, the screening against MCF-7 cell line, the compounds 7a, 7b and 7c showed 
significant activity with IC50 value ranging from 15±1.5 to 19±1.4 μM. While compounds 7g, 7h 
and 7i were moderately active with IC50 values of 18±1.7, 19±0.8 and 17±0.8 μΜ respectively. 
Subsequently, those compounds which showed good activity with MCF-7 were screened against 
A-549 cell line. Compounds 7e, 7f and 7d were the most active analogs through this study with 
IC50 values of 14±1.2, 16±1.5 and 15±1.4 μM respectively. In addition, compounds 7a, 7b and 
7c with 1C50 values ranging from 15±1.4 to 18±1.5 μΜ displayed substantial activity against A-
549 cell line whereas compounds 7g, 7h and 7i were moderately active with IC50 values of 
20±1.4, 18±1.4 and 21±1.4 μΜ respectively. In general, it was found that all the synthesized 
dispiro-carbazole derivatives displayed selective cytotoxicity against both the tested cell lines- 
A-549 and MCF-7 and finally, compound 7e was emerged as the most promising anticancer 
agent against MCF-7 and A-549 cell lines with IC50 values of 13±1.6 and 14±1.2 μM 
respectively. 
 
 
Figure 3. Cytotoxic effect of the compounds 7e & 7d on the viability of MCF-7 & A-549 cell lines 
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2.2.2. Structure activity relationship (SAR) 
Based on the aforementioned biological data, the following assumptions could be deduced 
about the structural activity relationship (SAR): 
❖ It is clear from the results summarized in Table 3 that the substitution attached to the 
pyrrolo group oriented at the C4'-position of the synthesized spiro heterocycle plays an 
important role in developing the observed anti-tumor properties. Among the synthesized 
compounds, the compound 6-chloro-4'-(thiophen-2-yl)-5'-phenyl-3,4-dihydrodispiro 
[carbazole-2,3'-pyrrolo-2',3''-indole]-9(H)-1,2''-dione 7e showed higher cytotoxic efficacy 
with 1C50 value 13±1.6 μM for MCF-7 and 14±1.2 μΜ for A-549 cell line. Compounds 
7d and 7f also exhibited stronger cytotoxic activity against both the tested cell lines. It 
was due to the presence of thiophene moiety [43,44] which boots the cytotoxic activity. 
❖ On the other hand, replacing the thiophene group at the C4'-position of the pyrrolo moiety 
by the electron donating methoxy group reduced the anticancer potency of the dispiro 
compounds. The compounds 7g, 7h and 7i having methoxy substitution on the pyrrolo 
ring showed moderate anticancer activities (Scheme. 4). 
 
❖ In general, it was observed that the substituent present in the carbazole ring plays a vital 
role in determining the anticancer potency. Among the dispiro-carbazole compounds, the 
compounds bearing electron withdrawing chloro group in the carbazole ring enhanced the 
cytotoxic activity more than the electron donating methyl group and unsubstituted group 
[45]. (Scheme. 5) 
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2.2.3. Apoptosis assay 
Apoptosis, the process of programmed cell death (PCD), is an important therapy target 
for cancer chemotherapy. Apoptotic cell death is morphologically defined by chromatin 
condensation, nuclear fragmentation, shrinkage of cytoplasm and formation of apoptotic bodies. 
The apoptotic events were analyzed using various staining procedures to study the cytotoxicity 
and cell viability, extent of apoptosis, morphological changes, nuclear changes and DNA 
fragmentation, which occurs at the final stage of apoptosis. The development of human cancers 
is often mainly a consequence of deregulated cell cycle control and/or suppressed apoptosis.  
 
2.2.3.1. Morphological changes of selected human cancer cell lines using  
Inverted Light Microscopic analysis.  
The apoptogenic property of the active dispiro compounds was investigated through 
morphological changes in MCF-7 and A-549 human cancer cells. Apoptotic cells displayed 
typical common features such as cell shrinkage, nuclear condensation, membrane blebbing, 
chromatin cleavage, and formation of pyknotic bodies of condensed chromatin. These distinctive 
typical forms of morphological changes in apoptotic cells are widely used for the identification 
and quantification of apoptosis. Thus, determination of the morphological changes to define 
apoptosis was visualized using inverted light microscopic technique. 
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Figure 4. Morphometric analysis of treated MCF-7 & A-549 cells, the arrows indicates the formation of 
floating cells and appearance of membrane blebbing 
 
Figure 4 shows the morphological changes in MCF-7 breast cancer and A-549 lung 
cancer cells after treatment with compounds with their respective inhibitory concentration for 24 
h in comparison to control cells. Visualization of the control (untreated) cells showed that the 
cells maintained their original morphology form. Phase-contrast micrographs revealed that the 
compounds 7e and 7d induces increased cell shrinkage, membrane blebbing and forms floating 
cells, compared to compounds 7a, 7b, 7c, 7f, 7g and 7h in a dose-dependent manner.  
 
2.2.3.2. Morphological observation of selected human cancer cell lines using Fluorescence 
Microscopic analysis. 
Fluorescence light microscopy with differential uptake of fluorescent DNA binding dyes 
(such as EB/AO, DAPI staining) is a method of choice for its simplicity, rapidity, and accuracy. 
In such an assay, apoptotic index and cell membrane integrity can be assessed simultaneously 
and there is no cell fixation step, thus avoiding a number of potential artifacts. Fluorescence 
microscopy analysis revealed the effects of synthesized compounds to induce apoptosis in MCF-
7 breast cancer and A-549 lung cancer cells. Induction of apoptosis is the most important 
mechanism for many anticancer agents. Fluorescence microscopic analysis of cell death showed 
that treatment of cells with compounds induce more apoptotic cell death rather than necrotic 
death. Mechanism of cell death was studied by nuclear staining methods such as AO/EB and 
DAPI staining methods. Staining cells with fluorescent dye is used in evaluating the nuclear 
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morphology of apoptotic cells. One of the characteristics of cells undergoing apoptosis is nuclear 
chromatin condensation. The DNA in condensed chromatin stains strongly with fluorescent dyes 
which allows for differentiation of apoptotic from non-apoptotic cells. 
 
2.2.3.2.1. 4',6-Diamidino-2-phenylindole (DAPI) staining method 
DAPI detection provides a rapid and convenient assay for apoptosis based upon 
fluorescent detection. DAPI (4',6-diamidino-2-phenylindole) is a fluorescent stain that binds 
strongly to A-T rich regions in DNA. Its high cell permeability allows efficient staining of 
nuclei. Once it overpasses cell membranes of normal cells, the blue fluorescence will be 
observed by fluorescent microscopy. With the process of apoptosis, the ability of permeability 
for dye is improved and the apoptotic cells will produce high blue fluorescence. Fluorescence 
microscopic images of breast cancer cells after 24 h stained with DAPI in the presence and 
absence of compounds are shown in Figure 5. The compounds 7e, 7d, 7c and 7f displayed 
higher level of nuclear fragmentation and the untreated cells did not show any significant 
changes in the nuclear appearance, whereas the other compounds exhibited bright fetches when 
treated with MCF-7 cancer cells, which indicates the condensed chromatins and nuclear 
fragmentations in the cells. Figure 5 showed fluorescent DAPI analysis of compounds treated A-
549 lung cancer cells. Compounds 7d and 7e exhibit higher level of nuclear fragmentation in the 
treated A-549 cells, rather than the remaining compounds 7a, 7b, 7c, 7f, 7h and 7g. The 
apoptosis observed in compounds which are treated with MCF-7 breast cancer cells are higher 
than that observed in A-549 lung cancer cells. 
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Figure 5. DAPI apoptotic analysis of treated MCF-7 & A-549 cells the arrows indicate apoptotic cells 
 
2.2.3.2.2. Acridine orange/ Ethidium bromide (AO/EB) staining method 
To confirm the induction of apoptosis, treated cells were visualized by fluorescence 
microscopy following treatment with 1:1 ratio of AO/EB, which allow differentiation of dead 
and viable cells by staining DNA. Fluorescence microscopy images of MCF-7 and A-549 cancer 
cells in the absence of compounds (control) and in the presence of compounds are shown Figure 
6. The untreated MCF-7 cancer cells did not show any significant adverse effect compared to the 
compounds treated cancer cells. It can be observed that the addition of compounds7e and 7d to 
the MCF-7 cancer cells, the fluorescence green colour of cells are changed to orange/red colour, 
which is due to induced apoptosis and nuclear condensation effect. The cells with intact 
membranes shows fluorescence green due to AO staining while EtBr stains cells with damaged 
membranes which exhibits orange/red fluorescence due to DNA intercalation of both stains. The 
rest of the compounds showed weak fluorescence intensity owing to the reduced level of 
induction of apoptosis in the MCF-7 cells. In the case of lung cancer cell, compounds 7d, 7e and 
7f exhibited significant apoptotic induction rather than the compounds 7a, 7b, 7c, 7g and 7h. The 
apoptotic induction values of the synthesized compounds were remarkable in MCF-7 cells 
compared to the lung cancer cells. 
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Figure 6. AO/EB apoptotic analysis of treated MCF-7 & A-549 cells the arrows indicate apoptotic cells 
 
2.2.3.2.3. Apoptotic analysis of Human cancer cells by flow cytometry 
To further confirm the dispiro hetrocycles-induced apoptosis, the apoptosis was detected 
by flow cytometric technique using the Annexin V method, with the aid of an Annexin V-FITC 
to perform double-staining with propidium iodide. Treatment with compound 7e shows a 
significant population of annexin-V positive cells (pro and late apoptotic cells) in the right hand 
quadrants of flow cytometric graphs in a dose dependent manner (Figure. 7). The compound 7e 
has the potential to stimulate the apoptotic signals and activate subsequent cell death 
mechanisms. Moreover the compound significantly active on MCF-7 cells rather than the A-549 
cells (Figure. 8). This activity may be the marker receptor present on the cell surface and it 
could be more active on breast cancer cells. These results indicate that dispiro heterocyclic 
compound induced cell death is mediated by the induction of apoptotic pathways in selected 
human cancer cells. 
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Figure 7. Flow cytometry analysis of breast cancer cells (MCF-7). Quadrant 4 represents necrotic cells 
(D-20μM/ml), Quadrant 3 represents late apoptotic cells (C-10μM/ml), Quadrant 2 represents 
proapoptotic cells (B-5μM/ml), and Quadrant 1 represents live cells (A-Control). 
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Figure 8. Flow cytometry analysis of Lung cancer cells (A-549). Quadrant 4 represents necrotic cells (D-
20μM/ml), Quadrant 3 represents late apoptotic cells (C-10μM/ml), Quadrant 2 represents proapoptotic 
cells (B-5μM/ml), and Quadrant 1 represents live cells (A-Control). 
 
3. Conclusions 
The present investigation describes the synthesis of new and highly functionalized 
carbazole containing dispiropyrrolooxindole hybrid molecules obtained through regio- and 
stereoselective 1,3-dipolar cycloaddition reaction of azomethineylide with (E)-2-
arylidine/heteroarylidine-2,3-4,9-tetrahydro-1H-carbazole-1-one as dipolarophiles. Interestingly, 
benzylamine played a critical role in the regioselectivity of this 1,3-cycloaddition to construct the 
4'-arylidene/heteroarylidene-5'-phenyl-3,4-dihydrodispiro[carbazole-2,3'-pyrrolo-2',3''-indole]-
9(H)-1,2''-dione ring system and it was obtained as a single regioisomer. The structural 
assignments of the corresponding cycloadducts were confirmed by FT-IR, NMR spectroscopy 
and the structure of compound 7a was further confirmed by X-ray crystallographic analysis. The 
cytotoxic efficacy of these compounds was assessed against the human cancer cell line MCF-7 
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and A-549 and all dispiro compounds were either equipotent or moderate to the positive control 
cisplatin. Among which, compounds 7e, 7f and 7g having thiophene moiety showed potent in 
vitro anti-proliferative activity. Moreover, the preliminary structure activity relationships of these 
derivatives have been established. The mode of cell death assessed by inverted light microscopic, 
fluorescence microscopic (DAPI staining and AO/EB dual staining procedures) techniques and 
flow cytometry analyses revealed that the dispiro-carbzole compounds were able to trigger 
apoptosis in both MCF-7 and A-549 human cancer cells lines. 
 
4. Experimental protocols 
4.1. Chemistry 
4.1.1. General 
All the chemicals were bought from Sigma-Aldrich and Merck and were utilized for the 
process without further purification. Melting points (M.p.) were determined on a Mettler FP 51 
apparatus (Mettler Instruments, Switzerland) and are uncorrected. They are expressed in degree 
centigrade (°C). FT-IR spectra were recorded on Avatar Model FT-IR (4000–400 cm-1) 
spectrophotometer. 1H NMR and 13C NMR spectra were recorded on a Agilent- 400 MHz (1H) 
and 100 MHz (13C) spectrometers respectively in CDCl3 using TMS (tetramethylsilane) as 
internal reference; chemical shifts are expressed in parts per million (ppm); coupling constants 
(J) are reported in hertz (Hz) and  the terms Jo and Jm refer to ortho coupling constant and meta 
coupling constant. The signals were characterized as s (singlet), d (doublet), t (triplet), m 
(multipiet), bs (broad singlet) and dd (doublet, and doublet). Microanalyses were carried out 
using Vario EL III model CHNS analyzer (Vario, Germany). When known compounds had to be 
prepared according to literature procedures and pertinent references are given. The purity of the 
products was tested by TLC plates coated with silica gel-G using petroleum ether and ethyl 
acetate in the ratio of 1:1 as developing solvents. 
 
4.1.2. Synthesis 
4.1.2.1. General procedure for the synthesis of 2-arylidene/heteroarylidene-2,3,4,9-
tetrahydrocarbazol-1-one 3. 
An equimolar mixture of the 2,3,4,9-tetrahydrocarbazol-1-one 1 (1.0 mmol) and 
aryl/heteroaryl aldehyde 2 (1.0 mmol) was treated with 5 % ethanolic KOH (25 mL) solution and 
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stirred for 24 h at room temperature. The completion of the reaction was monitored by TLC. 
After the completion of the reaction, the reaction mixture was cooled to room temperature and 
poured into ice cold water and neutralized with 1:1 HCl. The precipitated solid was filtered and 
purified by column chromatography over silica gel using petroleum ether: ethyl acetate (99:1) 
mixture as eluant to afford the respective product, 2-arylidene/heteroarylidene-2,3,4,9-
tetrahydrocarbazol-1-one 3. 
 
 
4.1.2.1.1. 2-Benzylidene-6-methyl-2,3,4,9-tetrahydro-1H-carbazol-1-one (3a). Yellow solid; 
yield: 244 mg (85%); m.p. 228-230 ͦC; FT-IR (KBr, cm-1) ѵmax: 3290 (NH), 1644 (C=O); 1H 
NMR (400 MHz, CDCl3) (ppm) δH: 11.64 (b s, 1H, N9-H), 8.27 (s, 1H, C5-H), 7.68-7.34 (m, 6H, 
C8, C6', C5', C4', C3' & C2'-H), 7.12-6.98 (m, 2H, C7 & C2-2H), 3.05-3.03 (m, 2H, C3-2H), 3.02-
3.00 (m, 2H, C4-2H), 2.50 (s, 3H, C6-CH3); 
13C NMR (100 MHz, CDCl3) (ppm) δC: 179.5 
(C=O), 138.4 (C2), 136.9 (C8a), 135.6 (C2a), 133.6 (C1'), 132.1 (C9a), 129.5 (C6), 128.4 (C5' & 
C3'), 128.1 (C6' & C2'), 127.7 (C4b), 126.7 (C4'), 124.9 (C4a), 122.4 (C7), 120.0 (C5), 118.5 (C8), 
27.2 (C3), 20.3 (C4), 17.0 (CH3); Anal. calcd. for C20H17NO: C, 83.59; H, 5.96; N, 4.87; Found: 
C, 83.50; H, 5.92; N, 4.93. 
 
4.1.2.1.2. 2-Benzylidene-6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-one (3b). Yellow solid; 
yield: 224 mg (73%); m.p. 231-233 ͦC; FT-IR (KBr, cm-1) ѵmax: 3324 (NH), 1652 (C=O); 1H 
NMR (400 MHz, CDCl3) (ppm) δH: 9.43 (b s, 1H, N9-H), 7.82 (s, 1H, C5-H), 7.62 (s, 1H, C2-H), 
7.44-7.30 (m, 7H, C8, C7, C6', C5', C4', C3' & C2'-H), 3.27-3.24 (m, 2H, C3-2H), 3.03-3.00 (m, 2H, 
C4-2H); 
13C NMR (100 MHz, CDCl3) (ppm) δC: 180.1 (C=O), 138.7 (C2), 137.3 (C8a), 135.9 
(C2a), 134.1 (C1'), 132.8 (C9a), 129.7 (C6), 128.7 (C5' & C3'), 128.5 (C6' & C2'), 128.2 (C4b), 126.3 
(C4'), 125.4 (C4a), 122.7 (C7), 120.3 (C5), 118.7 (C8), 27.3 (C3), 20.4 (C4); Anal. calcd. for 
C19H14ClNO: C, 74.15; H, 4.58; N, 4.55; Found: C, 74.25; H, 4.54; N, 4.61 . 
 
4.1.2.1.3. 2-Benzylidene-2,3,4,9-tetrahydro-1H-carbazol-1-one (3c). Yellow solid; yield: 227 mg 
(83%); m.p. 232-234 ͦC; FT-IR (KBr, cm-1) ѵmax: 3262 (NH), 1647 (C=O); 1H NMR (400 MHz, 
CDCl3) (ppm) δH: 9.51 (b s, 1H, N9-H), 7.84 (s, 1H, C2-H),  7.66 (d, 1H, C5-H, Jo = 7.8 Hz), 
7.49-7.33 (m, 7H, C8, C6,  C6', C5', C4', C3' & C2'-H), 7.15 (t, 1H, C7-H, J = 7.8 Hz), 3.28-3.25 
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(m, 2H, C3-2H), 3.09-3.06 (m, 2H, C4-2H); 
13C NMR (100 MHz, CDCl3) (ppm) δC: 179.3 
(C=O), 138.2 (C2), 136.7 (C8a), 135.4 (C2a), 133.8 (C1'), 132.3 (C9a), 129.2 (C6), 128.6 (C5' & 
C3'), 128.5 (C6' & C2'), 127.4 (C4b), 126.5 (C4'), 124.8 (C4a), 122.2 (C7), 120.3 (C5), 118.7 (C8), 
27.1 (C3), 20.4 (C4);  Anal calcd. for C19H15NO: C, 83.49; H, 5.53; N, 5.12; Found: C, 83.41; H, 
5.58; N, 5.5 . 
 
4.1.2.1.4. 6-Methyl-2-(thiophen-2-ylmethylene)-2,3,4,9-tetrahydro-1H-carbazol-1-one (3d). 
Yellow solid; yield: 243 mg (83%); m.p. 221-223 ͦC; FT-IR (KBr, cm-1) ѵmax: 3242 (NH), 1631 
(C=O); 1H NMR (400 MHz, CDCl3) (ppm) δH: 8.84 (b s, 1H, N9-NH), 7.96 (s, 1H, C2'-H), 7.50 
(d, 1H, C4'-H, J4',3' = 5.2 Hz), 7.44 (s, 1H, C5-H), 7.37 (d, 1H, C2'-H, J2',3' = 4.0 Hz), 7.32 (d, 1H, 
C8-H, Jo = 8.2 Hz), 7.21 (d, 1H, C7-H, Jo = 8.2 Hz), 7.13 (d d, 1H, C3'-H, J3',2' = 3.8 Hz & J3',4' = 
4.8 Hz), 3.37-3.33 (m, 2H, C3-2H), 3.15-3.13 (m, 2H, C4-2H), 2.45 (s, 3H, C6-CH3); Anal. calcd. 
for C18H15NOS: C, 73.69; H, 5.15; N, 4.77; Found: C, 73.60; H, 5.19; N, 4.83 . 
 
4.1.2.1.5. 6-Chloro-2-(thiophen-2-ylmethylene)-2,3,4,9-tetrahydro-1H-carbazol-1-one (3e). 
Yellow solid; yield: 223 mg (76%); m.p. 219-221 ͦC; FT-IR (KBr, cm-1) ѵmax: 3231 (NH), 1632 
(C=O); 1H NMR (400 MHz, CDCl3) (ppm) δH: 8.93 (b s, 1H, N9-H), 7.97 (s, 1H, C2-H), 7.64 (d, 
1H, C4'-H, J4',3' = 5.2 Hz), 7.52 (d, 1H, C2'-H, J2',3' = 5.2 Hz), 7.42-7.28 (m, 2H, C3' & C5-H), 
7.14-7.11 (m, 1H, C8-H), 7.06-7.04 (m, 1H, C7-H), 3.37-3.34 (m, 2H, C3-2H), 3.13-3.10 (m, 2H, 
C4-2H);
 13C NMR (100 MHz, CDCl3) (ppm) δC: 179.4 (C=O), 144.5 (C2a), 139.6 (C8a), 137.0 
(C1'), 132.4 (C2), 131.7 (C4'), 130.7 (C2'), 130.5 (C9a), 127.3 (C6), 126.6 (C3'), 125.3 (C4b), 124.1 
(C4a), 118.3 (C7), 116.6 (C5), 109.4 (C8), 24.6 (C3), 22.4 (C4); Anal. calcd. for C17H12ClNOS: C, 
65.07; H, 3.85; N, 4.46; Found: C, 65.16; H, 3.89; N, 4.40. 
 
4.1.2.1.6. 2-(thiophen-2-ylmethylene)-2,3,4,9-tetrahydro-1H-carbazol-1-one (3f). Yellow solid; 
yield: 223 mg (80%); m.p. 220--221 ͦC; FT-IR (KBr, cm-1) ѵmax: 3235 (NH), 1633 (C=O); 1H 
NMR (400 MHz, CDCl3) (ppm) δH: 8.96 (b s, 1H, N9-H), 7.97 (s, 1H, C2-H), 7.69-7.63 (m, 1H, 
C4'-H), 7.49-7.33 (m, 2H, C2' & C5-H), 7.18-7.10 (m, 3H, C8, C7 & C6-H), 7.04 (t, 1H, C3'-H, J = 
4.4 Hz), 3.18-3.07 (m, 4H, C3 & C4-2H); 
13C NMR (100 MHz, CDCl3) (ppm) δC: 180.2 (C=O), 
145.4 (C2a), 139.8 (C8a), 136.5 (C1'), 130.0 (C2), 127.9 (C4'), 125.8 (C4b), 124.0 (C2'), 123.1 
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(C9a), 122.7 (C3'), 121.7 (C4a), 116.6 (C7), 116.4 (C6), 115.7 (C5), 107.6 (C8), 24.9 (C3), 22.7 
(C4); Anal. calcd. for C17H13NOS: C, 73.09; H, 4.69; N, 5.01; Found: C, 73.01; H, 4.73; N, 5.07. 
 
4.1.2.1.7. 2-(4'-methoxybenzylidene)-6-methyl-2,3,4,9-tetrahydro-1H-carbazol-1-one (3g). 
Yellow solid; yield: 265 mg (87%); m.p. 222-224 ͦC; FT-IR (KBr, cm-1)ѵmax: 3321 (NH), 1630 
(C=O); 1H NMR (400 MHz, CDCl3) (ppm) δH: 8.89 (b s, 1H, N9-H), 7.74 (s, 1H, C2-H), 7.43-
7.41 (m, 3H, C5, C6' & C5'-H), 7.33-7.27 (m, 1H, C8-H), 7.21-7.18 (m, 1H, C7-H), 6.95 (d, 2H, 
C5' & C3'-H, Jo = 8.8 Hz), 3.85 (s, 3H, C4'-OCH3), 3.27-3.24 (m, 2H, C3-2H), 3.05-3.01 (m, 2H, 
C4-2H), 2.44 (s, 3H, C6-CH3); 
13C NMR (100 MHz, CDCl3) (ppm) δC: 179.8 (C=O), 159.5 (C4'), 
138.7 (C8a), 135.5 (C2), 134.3 (C2a), 132.2 (C6' & C2'), 131.7 (C4b), 128.4 (C9a), 127.5 (C1'), 126.7 
(C4a), 125.6 (C7), 121.5 (C6), 120.1 (C5), 114.0 (C5' & C3'), 112.4 (C8), 55.5 (OCH3), 27.7 (C3), 
24.8 (C4), 18.7 (CH3); Anal. calcd. for C21H19NO2: C, 79.47; H, 6.03; N, 4.41; Found: C, 79.54; 
H, 6.00; N, 4.47. 
 
4.1.2.1.8. 2-(4'-methoxybenzylidene)-6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-one (3h). 
Yellow solid; yield: 253 mg (78%); m.p. 220-222 ͦC; FT-IR (KBr, cm-1) ѵmax: 3235 (NH), 1641 
(C=O); 1H NMR (400 MHz, CDCl3) (ppm) δH: 9.87 (b s, 1H, N9-H), 7.81 (s, 1H, C2-H), 7.47-
7.45 (m, 3H, C5, C6' & C5'-H), 7.37-7.33 (m, 1H, C8-H), 7.26-7.22 (m, 1H, C7-H), 7.05 (d, 2H, 
C5' & C3'-H, Jo = 8.8 Hz), 3.83 (s, 3H, C4'-OCH3), 3.25-3.21 (m, 2H, C3-2H), 3.07-3.05 (m, 2H, 
C4-2H);  Anal. calcd. for C20H16ClNO2: C, 71.11; H, 4.77; N, 4.15; Found: C, 71.11; H, 4.77; N, 
4.15. 
 
4.1.2.1.9. 2-(4'-methoxybenzylidene)-2,3,4,9-tetrahydro-1H-carbazol-1-one (3i). Yellow solid; 
yield: 241 mg (83%); m.p. 224-226 ͦC; FT-IR (KBr, cm-1) ѵmax: 3267 (NH), 1642 (C=O); 1H 
NMR (400 MHz, CDCl3) (ppm) δH: 9.57 (b s, 1H, N9-H), 7.81 (s, 1H, C2-H), 7.65 (d, 2H, C6' & 
C2'-H, Jo = 8.4 Hz),  7.61-7.42 (m, 2H, C8 & C5-H), 7.38-7.34 (m, 1H, C6-H), 7.16-7.12 (m, 1H, 
C7-H), 6.98-6.94 (m, 2H, C5' & C3'-H, ), 3.85 (s, 3H, C4'-OCH3), 3.30-3.26 (m, 2H, C3-2H), 3.08-
3.05 (m, 2H, C4-2H); 
13C NMR (100 MHz, CDCl3) (ppm) δC: 181.0 (C=O), 159.7 (C4'), 138.6 
(C8a), 135.2 (C2), 134.5 (C2a), 132.4 (C6' & C2'), 131.5 (C4b), 128.0 (C9a), 127.0 (C1'), 126.9 (C4a), 
125.8 (C7), 121.3 (C6), 120.3 (C5), 113.9 (C5' & C3'), 112.6 (C8), 55.3 (OCH3), 27.6 (C3), 24.9 
(C4); Anal. calcd. for C20H17NO2: C, 79.19; H, 5.65; N, 4.62; Found: C, 79.10; H, 5.69; N, 4.68. 
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4.1.2.2. General procedure for the synthesis of 4'-arylidene/heteroarylidene-5'-phenyl-3,4-
dihydrodispiro[carbazole-2,3'-pyrrolo-2',3''-indole]-9(H)-1,2''-dione 7 
An appropriate mixture of 2-arylidene/heterolidene-2,3,4,9-tetrahydrocarbazol-1-one 3 
(1.0 mmol) isatin 4 (1.0 mmol) and bezylamine 5 (1.0 mmol) was refluxed in dioxane: methanol 
(1:1) for 5 h. After completion of the reaction, the solvent was removed in vacuum and crude 
product was subjected to silica gel column chromatography using petroleum ether: ethyl acetate 
(91:9) as eluant to yield the respective 4'-arylidene/heteroarylidene-5'-phenyl-3,4-
dihydrodispiro[carbazole-2,3'-pyrrolo-2',3''-indole]-9(H)-1,2''-dione 7. 
 
4.1.2.2.1. 6-Methyl-4',5'-diphenyl-3,4-dihydrodispiro[carbazole-2,3'-pyrrolo-2',3''-indole]-9(H)-
1,2''-dione (7a). White solid; yield: 455 mg (87%); m.p. 216-218 ͦC; FT-IR (KBr, cm-1) ѵmax: 
3419 (Indole NH), 3322 (carbazole NH), 3222 (pyrrolo NH), 1696 (indole C=O), 1617 
(carbazole C=O); 1H NMR (400 MHz, CDCl3) (ppm) δH: 11.18 (b s, 1H, N9-H), 10.18 (b s, 1H, 
N1''-H), 7.50 (d, 2H, C8 & C7''-H, Jo = 7.4 Hz), 7.38 (m, 2H, C5'''' & C3''''-H), 7.26-7.22 (m, 4H, 
C6''',C5''', C3''' & C2'''-H), 7.18-7.13 (m, 3H, C6'', C6'''' & C2''''-H), 7.09 (s, 1H, C5-H), 7.05 (d, 1H, 
C4''-H, Jo = 7.4 Hz), 6.97 (d, 1H, C7-H, Jo = 7.4 Hz), 6.84 (t, 1H, C5''-H, J = 7.4 Hz), 6.56 (t, 1H, 
C4'''-H, J = 7.2Hz), 6.54 (t, 1H, C4''''-H, J = 7.2 Hz), 5.45 (d d, 1H, C5'-H, J1,2-cis = 5.6 Hz & J1,2 -
cis = 10.0 Hz), 4.69 (d, 1H, C4'-H, Jcis = 10.0 Hz), 3.61 (d, 1H, pyrrolo NH, J1,2-cis = 5.6 Hz), 2.58-
2.56 (m, 2H, C4-H), 2.48-2.45 (m, 2H, C3-H) 2.22 (s, 3H, C6-CH3); 
13C NMR (100 MHz, CDCl3) 
(ppm) δC: 191.5 (C=O), 180.5 (C=O), 143.3 (C3a''), 142.2 (C7a''), 139.2 (C1'''), 137.2 (C8a), 131.9 
(C1''''), 129.6 (C9a), 128.9 (C5''), 128.9 (C6), 128.5 (C5''' & C3'''), 128.4 (C5'''' & C3''''), 127.9 (C6''' 
& C2'''), 127.5 (C6'''' & C2''''), 127.0 (C4b), 126.7 (C6''), 126.1 (C4''' & C4''''), 125.1 (C4''), 121.1 
(C4a), 120.5 (C7), 112.7 (C5 & C8), 109.5 (C7''), 72.3 (spiro indole carbon C3''), 63.8 (C5'), 61.5 
(spiro carbazole carbon C2), 58.3 (C4'), 32.1 (C4), 21.3 (CH3), 18.5 (C3); Anal. calcd. for 
C35H29N3O2: C, 80.28; H, 5.58; N, 8.02; Found: C, 80.36; H, 5.53; N, 8.08. 
 
4.1.2.2.2. 6-Chloro-4',5'-diphenyl-3,4-dihydrodispiro[carbazole-2,3'-pyrrolo-2',3''-indole]-9(H)-
1,2''-dione (7b). White solid; yield: 504 mg (93%); m.p. 212-214 ͦC; FT-IR (KBr, cm-1) ѵmax: 
3416 (Indol NH), 3322 (carbazole NH), 3220 (pyrrolo NH), 1695 (indole C=O), 1622 (carbazole 
C=O); 1H NMR (400 MHz, CDCl3) (ppm) δH: 10.85 (b s, 1H, N9-H), 10.02 (b s, 1H, N1''-H), 
7.49 (d, 2H, C8 & C7''-H, Jo = 7.4 Hz), 7.40 (d, 2H, C5'''' & C3''''-H, Jo = 6.0 Hz), 7.19-7.04 (m, 
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8H, C5, C5''', C3''', C4''', C6'''', C2'''', C6'' & C4'-H), 7.00 (d, 2H, C6''' & C2'''-H, Jo = 8.6 Hz), 6.76 (t, 
1H, C6'-H, Jo = 7.4 Hz), 6.54-6.46 (m, 2H, C5'' & C7-H), 5.47 (d, 1H, C5'-H, J1,2-cis = 8.0 Hz), 
4.75 (d, 1H, C4'-H, J1,2-cis = 10.0 Hz), 261-2.50 (m, 2H, C4-2H), 1.46-1.39 (m, 2H, C3-2H); 
13C 
NMR (100 MHz, CDCl3) (ppm) δC: 192.3 (C=O), 179.8 (C=O), 141.9 (C3a''), 141.7 (C7a''), 138.6 
(C1'''), 136.9 (C1''''), 132.6 (C8a), 130.6 (C5''), 128.9 (C9a), 128.2 (C6''' & C2'''), 128.1 (C6'''' & 
C2''''), 127.6 (C5''' & C3'''), 127.3 (C5'''' & C3''''), 126.8 (C4'''), 126.7 (C4''''), 126.3 (C4b), 125.3 (C6), 
124.8 (C5 & C7), 121.3 (C6'' & C4''), 119.9 (C4a), 114.0 (C7''), 109.6 (C8), 78.0 (spiro indol carbon 
C3''), 64.7 (C5'), 62.2 (spiro carbazole carbon C2), 58.5 (C4'), 31.8 (C4), 18.5 (C3); Anal. calcd. for 
C34H26ClN3O2: C, 75.06; H, 4.82; N, 7.72; Found: C, 75.15; H, 4.78; N, 7.66. 
 
4.1.2.2.3. 4',5'-Diphenyl-3,4-dihydrodispiro[carbazole-2,3'-pyrrolo-2',3''-indole]-9(H)-1,2''-
dione (7c). White solid; yield: 417 mg (82%); m.p. 214-216 ͦC; FT-IR (KBr, cm-1) ѵmax: 3374 
(Indol NH), 3307 (carbazole NH), 3229 (pyrrolo NH), 1687 (indole C=O), 1636 (carbazole 
C=O); 1H NMR (400 MHz, CDCl3) (ppm) δH: 10.50 (b s, 1H, N9-H), 9.98 (b s, 1H, N1''-H), 7.50 
(t, 2H, C5'''' & C3''''-H, J = 7.2 Hz), 7.41 (d, 2H, C8 & C5-H, Jo = 7.2Hz), 7.24-7.04 (m, 11H, C7'', 
C5''', C3''', C6''', C2''', C6'''', C2'''', C4'', C4''', C4'''' & C6''-H), 6.82 (t, 1H, C5''-H, J = 7.2 Hz), 6.78-
6.74 (m, 1H, C6-H), 6.50-6.48 (m, 1H, C7-H), 5.47 (d, 1H, C5'-H, Jo = 10.2 Hz), 4.76 (d, 1H, C4'-
H, J1,2-cis = 10.2 Hz), 2.60-2.46 (m, 2H, C4-2H), 1.48-1.43 (m, 2H, C3-2H); 
13C NMR (100 MHz, 
CDCl3) (ppm) δC: 197.0 (C=O), 184.6 (C=O), 146.7 (C3a''), 146.5 (C7a''), 143.5 (C1'''), 143.4 
(C8a), 136.3 (C1''''), 135.4 (C5''), 133.6 (C9a), 133.2 (C5''' & C3'''), 133.0 (C5'''' & C3''''), 132.8 (C4b), 
132.7 (C6''' & C2''') 132.4 (C6'''' & C2''''), 132.0 (C4'''), 131.4 (C4''''), 130.9 (C6'' & C4''), 130.1 (C7), 
129.7 (C4a), 126.1 (C6), 125.6 (C5), 124.2 (C6''), 117.4 (C8), 114.3 (spiro indol carbon C3''), 69.6 
(C5'), 67.1 (spiro carbazole carbon C2), 63.6 (C4'), 36.7 (C4), 23.4 (C3); Anal. calcd. for 
C34H27N3O2: C, 80.13; H, 5.34; N, 8.25; O, 6.28; Found: C, 80.06; H, 5.38; N, 8.18. 
 
4.1.2.2.4. 6-Methyl-4'-(thiophen-2-yl)-5'-phenyl-3,4-dihydrodispiro[carbazole-2,3'-pyrrolo-2',3''-
indole]- 9(H)-1,2''-dione (7d). White solid; yield: 423 mg (80%); m.p. 196-198 ͦC; FT-IR (KBr, 
cm-1) ѵmax: 3423 (Indole NH), 3392 (carbazole NH), 3263 (pyrrolo NH), 1697 (indol C=O), 1618 
(carbazole C=O); 1H NMR (400 MHz, CDCl3) (ppm) δH: 8.65 (b s, 1H, N9-H), 7.79 (b s, 1H, 
N1''-H), 7.67-7.65 (m, 2H, C5'''' & C3''''-H), 7.32-7.28 (m, 2H, C4''' & C7''), 7.24-7.21 (m, 1H, C8-
H), 7.18 (s, 1H, C5-H), 7.16-7.07 (m, 5H, C6'''',C2'''', C4'''', C4''& C6''-H), 6.93-6.89 (m, 2H, C5'' & 
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C7-H), 6.69-6.65 (m, 1H, C3'''-H), 6.62 (d, 1H, C2'''-H, Jo = 7.6 Hz), 5.48 (d, 1H, C5'-H, J1,2-cis = 
9.0 Hz), 5.06 (d, 1H, C4'-H, J1,2-cis = 9.0 Hz), 2.70-2.68 (m,2H, C4-H), 2.65-2.64 (m, 1H, C3b-H), 
2.33 (s, 3H, C6-CH3), 1.91-1.97 (m, 1H, C3a-H); 
13C NMR (100 MHz, CDCl3) (ppm) δC: 191.7 
(C=O), 179.6 (C=O), 141.3 (C3a''), 141.1 (C1'''), 140.2 (C7a''), 136.7 (C8a), 131.3 (C1''''), 129.5 
(C5''), 129.2 (C9a), 129.1 (C6), 128.5 (C5'''' & C3''''), 128.3 (C6'''' & C2''''), 128.1 (C4b), 127.7 (C3'''), 
127.6 (C6''), 126.7 (C4''''), 125.7 (C4''' & C2'''), 125.5 (C4''), 124.5 (C4a), 122.2 (C7), 120.5 (C5), 
111.8 (C7''), 109.3 (C8), 73.2 (spiro indol carbon C3'), 66.9 (C5'), 62.1 (spiro carbazole carbon 
C2), 53.9 (C4'), 30.8 (C4), 21.2 (C3), 18.6 (CH3); Anal. calcd. for C33H27N3O2S: C, 74.83; H, 
5.14; N, 7.93; Found: C, 74.94; H, 5.10; N, 7.99. 
 
4.1.2.2.5. 6-Chloro-4'-(thiophen-2-yl)-5'-phenyl-3,4-dihydrodispiro[carbazole-2,3'-pyrrolo-
2',3''-indole]- 9(H)-1,2''-dione (7e). White solid; yield: 401 mg (73%); m.p. 194-196 ͦC; FT-IR 
(KBr, cm-1) ѵmax: 3427 (Indol NH), 3329 (carbazole NH), 3225 (pyrrolo NH), 1696 (indol C=O), 
1620 (carbazole C=O); 1H NMR (400 MHz, CDCl3) (ppm) δH: 10.51 (b s, 1H, N9-H), 9.71 (b s, 
1H, N1''-H), 7.43 (d, 2H, C9 & C7''-H, Jo = 6.8 Hz), 7.12-6.98 (m, 5H, C5, C5'''',C3'''', C4''' & C6''-
H), 6.94-6.88 (3H, C6'''', C2'''' & C4''''-H), 6.85 (d, 1H, C4''-H, Jo = 7.4 Hz), 6.72-6.70 (m, 1H, C7-
H), 6.66 (t, 1H, C5''-H, J = 7.4 Hz), 6.41 (d, 1H, C2'''-H, Jo = 8.0 Hz), 6.35 (t, 1H, C3'''-H, J = 8.0 
Hz), 5.26 (d, 1H, C5'-H, J1,2-cis = 9.4 Hz), 4.80 (d, 1H, C4'-H, J1,2-cis  = 9.4 Hz), 2.45-2.35 (m, 3H, 
C3a & C4-H), 1.63-1.54 (m, 1H, C3b-H); 
13C NMR (100 MHz, CDCl3) (ppm) δC: 192.0 (C=O), 
179.3 (C=O), 141.5 (C3a''), 141.6 (C1'''), 140.4 (C7a''), 136.3 (C8a), 131.8 (C1''''), 129.7 (C5''), 
129.4 (C9a), 129.2 (C6), 128.7 (C5'''' & C3''''), 128.5 (C6'''' & C2''''), 128.0 (C4b), 127.9 (C3'''), 127.3 
(C6''), 126.4 (C4''''), 125.9 (C4''' & C2'''), 125.3 (C4''), 124.7 (C4a), 122.5 (C7), 120.1 (C5), 112.0 
(C7''), 109.7 (C8), 73.4 (spiro indole carbon C3''), 67.1 (C5'), 62.3 (spiro carbazole carbon C2), 
54.1 (C4'), 31.0 (C4), 21.3 (C3); Anal .calcd. for C32H24ClN3O2S: C, 69.87; H, 4.40; N, 7.64; 
Found: C, 69.96; H, 4.44; N, 7.70. 
 
4.1.2.2.6. 4'-(Thiophen-2-yl)-5'-phenyl-3,4-dihydrodispiro[carbazole-2,3'-pyrrolo-2',3''-indole]-
9(H)-1,2''-dione (7f). White solid; yield: 406 mg (79%); m.p. 198-200 ͦC; FT-IR (KBr, cm-1) 
ѵmax: 3376 (Indole NH), 3314 (carbazole NH), 3275 (pyrrolo NH), 1685 (indol C=O), 1642 
(carbazole C=O); 1H NMR (400 MHz, CDCl3) (ppm) δH: 8.69 (b s, 1H, N9-H), 7.78 (b s, 1H, 
N1''-H), 7.67 (d, 2H, C5'''' & C3''''-H, Jo = 7.2 Hz), 7.37 (d, 1H, C5-H), 7.33-7.22 (m, 4H, C8, C4''', 
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C7'' & C4''-H), 7.18-7.12 (m, 4H, C6'''', C2'''', C4'''' & C6''-H), 7.00 (t, 1H, C5''-H, J = 7.2 Hz), 6.94-
6.89 (m, 2H, C7 & C6-H), 6.67 (t, 1H, C3'''-H, J = 7.6 Hz), 6.62 (d, 1H, C2'''-H, Jo = 7.6 Hz),  5.50 
(d, 1H, C5'-H, J1,2-cis = 9.4 Hz), 5.06 (d, 1H, C4'-H, J1,2-cis = 9.4 Hz), 2.73-2.63 (m, 3H, C3a & C4-
H), 1.91-1.88 (m, 1H, C3b-H); 
13C NMR (100 MHz, CDCl3) (ppm) δC: 191.3 (C=O), 179.9 
(C=O), 141.4 (C3a''), 141.8 (C1'''), 140.4 (C7a''), 135.2 (C8a), 131.5 (C1''''), 129.3 (C5''), 129.1 
(C9a), 129.0 (C6), 128.7 (C5'''' & C3''''), 128.5 (C6'''' & C2''''), 128.3 (C4b), 127.5 (C3'''), 127.4 (C6''), 
126.9 (C4''''), 125.6 (C4''' & C2'''), 125.7 (C4''), 124.3 (C4a), 122.6 (C7), 121.2 (C5), 111.6 (C7''), 
109.5 (C8), 73.6 (spiro indole carbon C3'), 66.5 (C5'), 62.3 (spiro carbazole carbon C2), 53.7 (C4'), 
30.6 (C4), 21.4 (C3); Anal. calcd. for C32H25N3O2S: C, 74.54; H, 4.89; N, 8.15; Found: C, 74.53; 
H, 4.85; N, 8.21. 
 
4.1.2.2.7.6-Methyl-4'-(4'''-methoxyphenyl)-5'-phenyl-3,4-dihydrodispiro[carbazole-2,3'-pyrrolo-
2',3''-indole]-9(H)-1,2''-dione (7g). White solid; yield: 407 mg (85%); m.p. 200-202 ͦC; FT-IR 
(KBr, cm-1) ѵmax: 3420 (Indol NH), 3378 (carbazole NH), 3241 (pyrrolo NH), 1689 (indole 
C=O), 1643 (carbazole C=O); 1H NMR (400 MHz, CDCl3) (ppm) δH: 8.78 (b s, 1H, N9-H), 7.93 
(b s, 1H, N1''-H), 7.60 (d, 2H, C6''' & C2'''-H, Jo = 7.6 Hz), 7.43 (d, 2H, C8 & C7''-H, Jo = 7.6 Hz), 
7.33-7.25 (m, 2H, C6'''' & C2''''-H), 7.20 (t, 3H, C5'''', C3'''' & C4''''-H, Jo =7.2 Hz), 7.11 (s, 1H, C5-
H), 7.07 (d, 1H, C4''-H, Jo = 7.6 Hz), 6.90 (t, 1H, C6''-H, J = 7.6 Hz), 6.80 (d, 2H, C5''' & C3'''-H, 
Jo = 8.4 Hz), 6.68 (t, 1H,C5''-H, J=7.6 Hz), 6.61 (d, 1H, C7-H, Jo = 7.6 Hz),  5.52 (d, 1H, C5'-H, 
J1,2-cis = 9.6 Hz), 4.80 (d, 1H, C4'-H, J1,2-cis = 9.6 Hz),  3.74 (s, 3H, OCH3), 2.69-2.53 (m, 3H, C3a 
& C4-H), 2.31 (s, 3H, CH3), 1.69-1.63 (m, 1H, C3b-H); 
13C NMR (100 MHz, CDCl3) (ppm) δC: 
192.3 (C=O), 180.0 (C=O), 158.4 (C4'''), 141.6 (C3a''), 140.2 (C8a), 136.7 (C7a''), 131.6 (C1''''), 
131.4 (C5''), 130.3 (C9a), 129.4 (C1'''), 129.1 (C6''' & C2'''), 128.9 (C6), 128.5 (C5'''' & C3''''), 128.4 
(C6'''' & C2''''), 128.3 (C4b), 127.5 (C6''), 127.3 (C4''''), 125.8 (C4''), 125.5 (C4a), 122.2 (C7), 120.5 
(C5), 113.6 (C7''), 111.8 (C5''' & C3'''), 109.3 (C8), 73.1 (spiro indole carbon C3''), 65.5 (C5'), 62.4 
(spiro carbazole carbon C2), 58.1 (C4'), 55.0 (OCH3), 31.8 (C4), 21.2 (CH3), 18.7 (C3); Anal. 
calcd. for C36H31N3O3: C, 78.10; H, 5.64; N, 7.59; O, 8.67; Found: C, 78.19; H, 5.59; N, 7.52. 
 
4.1.2.2.8. 6-Chloro-4'-(4'''-methoxyphenyl)-5'-phenyl-3,4-dihydrodispiro[carbazole-2,3'-pyrrolo-
2',3''-indole]-9(H)-1,2''-dione (7h). White solid; yield: 517 mg (90%); m.p. 201-203 ͦC; FT-IR 
(KBr, cm-1) ѵmax: 3410 (Indole NH), 3371 (carbazole NH), 3315 (pyrrolo NH), 1686 (indole 
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C=O), 1651 (carbazole C=O); 1H NMR (400 MHz, CDCl3) (ppm) δH: 11.51 (b s, 1H, N9-H), 
10.42 (b s, 1H, N1''-H), 7.49 (d, 2H, C7'' & C8-H, Jo = 7.2 Hz), 7.41 (s, 1H, C5-H), 7.30-7.24 (m, 
5H, C5'''', C3'''', C6''', C2''' & C4''''-H),  7.18-7.12 (m, 2H, C6'''' & C2''''-H), 7.00 (d, 1H, C4''-H, Jo = 
7.2 Hz), 6.85-6.80 (m, 3H, C6'', C5'' & C7-H), 6.56-6.53 (m, 2H, C5''' & C3'''-H), 5.37 (d d, 1H, 
C5'-H, J1,2-cis = 5.6 Hz & J1,2 cis = 9.6 Hz), 4.58 (d, 1H, C4'-H, J1,2-cis = 9.6 Hz),  3.66 (s, 3H, 
OCH3),  3.63 (d, 1H, pyrrolo C1'-NH, J1,2 cis = 5.6 Hz), 2.65-2.54 (m, 3H, C3a & C4-H), 1.28-1.25 
(m, 1H, C3b-H); 
13C NMR (100 MHz, CDCl3) (ppm) δC: 193.0 (C=O), 183.1 (C=O), 158.6 (C4'''), 
141.5 (C3a''), 140.7 (C8a), 136.4 (C7a''), 132.3 (C1''''), 131.7 (C5''), 131.0 (C9a), 129.7 (C1'''), 129.5 
(C6''' & C2'''), 128.6 (C6), 128.7 (C5'''' & C3''''), 128.2 (C6'''' & C2''''), 128.0 (C4b), 127.3 (C6''), 
127.1 (C4''''), 126.3 (C4''), 125.7 (C4a), 122.4 (C7), 120.7 (C5), 113.3 (C7''), 112.1 (C5''' & C3'''), 
109.7 (C8), 73.4 (spiro indole carbon C3''), 66.4 (C5'), 62.8 (spiro carbazole carbon C2), 58.3 
(C4'), 55.5 (OCH3), 31.6 (C4), 18.9 (C3); Anal. calcd. for C35H28ClN3O3: C, 73.23; H, 4.92; N, 
7.32; Found: C, 73.12; H, 4.96; N, 7.25. 
 
4.1.2.2.9.4'-(4'''-Methoxyphenyl)-5'-phenyl-3,4-dihydrodispiro[carbazole-2,3'-pyrrolo-2',3''-
indole]-9(H)-1,2''-dione (7i). White solid; yield: 463 mg (86%); m.p. 202-204 ͦC; IR (KBr, cm-
1)ѵmax: 3439 (Indole NH), 3374 (carbazole NH), 3217 (pyrrolo NH), 1685 (indole C=O), 1643 
(carbazole C=O); 1H NMR (400 MHz, CDCl3) (ppm) δH: 11.30 (b s, 1H, N9-H), 10.41 (b s, 1H, 
N1''-H), 7.50 (d, 2H, C8 & C5-H, Jo = 7.2 Hz), 7.34 (d, 1H, C7''-H, Jo = 7.8 Hz), 7.27-7.23 (m, 
5H, C5'''', C3'''', C6''', C2''' & C4''''-H),  7.18-7.12 (m, 2H, C6'''' & C2''''-H), 7.04 (d, 1H, C4''-H, Jo = 
7.8 Hz), 6.88-6.79 (m, 4H, C6'', C5'' C7 & C6-H), 6.57-6.53 (m, 2H, C5''' & C3'''-H), 5.37 (d d, 1H, 
C5'-H, J1,2-cis = 5.6 Hz & J1,2 cis = 10.0 Hz), 4.61 (d, 1H, C4'-H, J1,2-cis = 10.0 Hz),  3.65 (s, 3H, 
OCH3),  3.60 (d, 1H, pyrrolo C1'-NH, J1,2 cis = 5.6 Hz), 2.61-2.57 (m, 3H, C3a & C4-H), 1.31-1.28 
(m, 1H, C3b-H); 
13C NMR (100 MHz, CDCl3) (ppm) δC: 191.8 (C=O), 180.6 (C=O), 158.3 (C4'''), 
143.5 (C3a''), 142.2 (C7a''), 138.7 (C8a), 131.8 (C1''''), 131.6 (C5''), 130.8 (C9a), 129.6 (C1'''), 128.9 
(C6''' & C2'''), 128.4 (C5'''' & C3''''), 127.9 (C4b), 127.4 (C6'''' & C2''''), 127.2 (C6''), 126.4 (C4''''), 
126.1 (C4''), 124.9 (C3a), 121.3 (C7), 121.1 (C6), 119.7 (C5), 113.9 (C7''), 113.0 (C5''' & C3'''), 
109.1 (C8), 72.3 (spiro indole carbon C3''), 64.0 (C5'), 61.4 (spiro carbazole carbon C2), 57.7 
(C4'), 55.2 (OCH3), 32.5 (C4), 18.5 (C3);  Anal. calcd. for C35H29N3O3: C, 77.90; H, 5.42; N, 
7.79. Found: C, 77.99; H, 5.37; N, 7.74. 
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4.2. Biological evaluation 
4.2.1. In vitro cytotoxic activity 
4.2.1.1. Cell line and cell culture 
The Human lung and breast cancer cells were purchased from the National Center for 
Cell Sciences (NCCS), Pune, India. The cancer cells were maintained in Dulbecco’s modified 
eagles medium (DMEM) supplemented with 2mM l-glutamine and balanced salt solution (BSS) 
adjusted to contain 1.5 g/L Na2CO3, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 2 
mM l-glutamine, 1.5 g/L glucose, 10 mM (4-(2-hydroxyethyl)-1-piperazineethane sulfonic acid) 
(HEPES) and 10% fetal bovine serum (GIBCO, USA). Penicillin and streptomycin (100 
IU/100µg) were adjusted to 1mL/L. The cells were maintained at 37◦C with 5% CO2 in a 
humidified CO2 incubator. 
 
4.2.1.2. In vitro assay 
The inhibitory concentration (IC50) value was evaluated using an MTT [3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay. Cancer cells were grown (1×104 
cells/well) in a 96-well plate for 48 h in to 75% confluence. The medium was replaced with fresh 
medium containing serially diluted synthesized compounds, and the cells were further incubated 
for 48 h. The culture medium was removed, and 100µL of the MTT [3-(4,5-dimethylthiozol-2-
yl)-3,5-diphenyl tetrazolium bromide] (Hi-Media) solution was added to each well and incubated 
at 37 ◦C for 4 h. After removal of the supernatant, 50 µL of DMSO was added to each of the 
wells and incubated for 10 min to solubilize the formazan crystals. The optical density was 
measured at 620 nm in an ELISA multiwell plate reader (ThermoMultiskan EX, USA). 
 
4.2.2. Cell morphology analysis 
The MCF-7 and A-549 cells that were grown on cover slips (1×105 cells/cover slip) 
incubated for 6-24 h with compounds at the IC50 concentration, and they were then fixed in an 
ethanol:acetic acid solution (3:1; v/v). The cover slips were gently mounted on glass slides for 
the morphometric analysis. Three monolayers per experimental group were photo micrographed. 
The morphological changes of the MCF-7 and A-549selected cells were analyzed using Nikon 
(Japan) bright field inverted light microscopy at 40x magnification. 
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4.2.3. Fluorescence microscopic analysis of apoptotic cell death 
Approximately 1µL of a dye mixture (100 mg/mL acridine orange (AO) and 100 mg/mL 
ethidium bromide (EtBr) in distilled water) was mixed with 9 mL of cell suspension (1×105 
cells/mL) on clean microscope cover slips. The selected cancer cells were collected, washed with 
phosphate buffered saline (PBS) (pH 7.2) and stained with 1 mL of AO/EtBr. After incubation 
for 2 min, the cells were washed twice with PBS (5 min each) and visualized under a 
fluorescence microscope (Nikon Eclipse, Inc, Japan) at 400× magnification with an excitation 
filter at 480 nm. Likewise the cells were plated on glass coverslip in a 24-well plate and treated 
with complex for 24h. The fixed cells were permeabilised with 0.2% triton X-100 (50μl) for 
10min at room temperature and incubated for 3min with 10μl of DAPI by placing a coverslip 
over the cells to enable uniform spreading of the stain. The cells were observed under (Nikon 
Eclipse, Inc, Japan) fluorescent microscope. 
 
4.2.4. Flow cytometry analysis 
The apoptotic eﬀect of synthesized dispiro compound 7e on MCF-7 and A-549 cells were 
determined by the annexin V-FITC and Propidium iodide double staining flow cytometric 
method. Initially cells (1x105 cells per ml) were treated with various concentrations and 
incubated for 6 h. The treated cells were harvested, washed with PBS, and then treated with 
trypsin/ EDTA solution. The suspended cells were centrifuged at 200xg for 10 min. To the cell 
pellet was added 100 ml of annexin V-FITC staining solution (Strong Biotech Co., Taipei, 
Taiwan) and the solution incubated for 10-15 min at 25oC. The cells were then analyzed with a 
flow cytometry (FACS verse, BD Bioscience, USA). 
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Supplementary data 
CIF files for the compounds 7a have been deposited with the Cambridge Crystallographic 
Data Centre as CCDC number1538472 respectively. Copies of the data can be obtained, free of 
charge, on application to CCDC, 12 Union Road, Cambridge, CB2 1EZ, UK. [Fax: +44 (0) 1223 
336033 or e-mail: deposit@ccdc.cam.ac.uk.Spectral data of all the compounds are associated 
with this article will be available as supporting information. 
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